# A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders

> **NCT04739423** · PHASE2 · COMPLETED · sponsor: **CuraSen Therapeutics, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

## Interventions

- **DRUG:** clenbuterol (CST-103), nadolol (CST-107), matching placebo

## Key facts

- **NCT ID:** NCT04739423
- **Lead sponsor:** CuraSen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-28
- **Primary completion:** 2022-07-04
- **Final completion:** 2022-08-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739423, "A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04739423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*